AMACR and inflammatory bowel disease: Although a recently published paper suggested that p53 nuclear staining and alpha-methylacyl-CoA racemase (AMCAR) immunoreactivity in biopsies with flat LGD and IND predicts progression to advanced IBD-associated neoplasia in a time period of 19 months [22], our study is the first to demonstrate the predictive value of p53 overexpression by immunohistochemistry in a specific, histologically challenging population, i.e. IBD patients with IND.